Glyxambi is a combination oral medication that contains empagliflozin and linagliptin. It is prescribed to improve glycemic control in adults with type 2 diabetes. The drug works by enhancing renal glucose excretion and suppressing intestinal carbohydrate absorption. Empagliflozin blocks the sodium-glucose cotransporter 2 in the kidney, leading to increased urinary glucose loss. Linagliptin inhibits dipeptidyl peptidase-4, raising levels of incretin hormones that promote insulin release. Together these actions lower blood sugar and reduce cardiovascular risk.

Glyxambi is a prescription medication indicated for the treatment of type 2 diabetes mellitus. It combines the active ingredients empagliflozin and linagliptin in a single tablet formulation. The drug functions as a dual inhibitor targeting the sodium glucose transporter 2 pathway and enhancing incretin hormone activity. By blocking glucose reabsorption in the kidneys it reduces circulating glucose levels and simultaneously enhances insulin secretion and pancreatic beta cell function to improve overall glycemic control. This coordinated pharmacological activity supports sustained glucose homeostasis without reliance on exogenous insulin administration. The combined mechanism provides additive therapeutic benefit while maintaining a favorable safety profile in appropriate patient populations.

The most common side effects are often mild and short lived. They may include headache fatigue dizziness or nausea. These reactions usually appear soon after dosing and resolve without intervention. Severity varies among individuals based on age health status and dose. Most people experience only temporary discomfort that does not require professional attention. Monitoring for unusual or persistent symptoms is advisable. Understanding typical responses helps individuals stay informed about their health.

The most common side effects include mild fatigue that many people experience early in treatment. Headaches are also frequently reported during the initial adjustment period. Nausea and occasional stomach discomfort often appear within the first few days. Dizziness and mild drowsiness can occur especially when starting new dosages. Some individuals notice changes in appetite or weight fluctuations over time. Emotional reactions such as irritability or mood swings are documented in clinical data. These effects typically lessen as the body adapts and treatment continues.